Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpibectir/Ethionamide in Tuberculosis Meningitis
NCT07350174Phase 2Not yet recruiting
- Sponsor
- BioVersys AG
- Start
- Mar 2026
- Primary completion
- Mar 2028
01
Overview
A Phase 2 trial of alpibectir in tuberculous meningitis (TBM), sponsored by BioVersys AG. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
alpibectir
03
Conditions
tuberculous meningitis (TBM)
Beyond the preview
Go deeper on NCT07350174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350174.